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OBJECTIVES We sought to study adenoviral gene delivery using percutaneous selective pressure-regulated
retroinfusion and to compare it directly with surgical and percutaneous intramyocardial
delivery (PIMD) for the first time.
BACKGROUND Intramyocardial delivery (IMD) has been recommended to be the preferred gene delivery
strategy so far. However, surgical and percutaneous intramyocardial injection lead to
incomplete retention of the injected viral vectors and to limited spatial myocardial distribu-
tion. Percutaneous selective pressure-regulated retroinfusion of the coronary veins was
developed recently to provide an effective and more homogenous regional myocardial gene
transfer.
METHODS In 15 pigs, adenoviral vectors (Ad2-CMV beta-galactosidase [-gal] 5  109 pfu) were
applied via surgical IMD (n  5), PIMD (n  5), and selective pressure-regulated
retroinfusion (n  5). Seven days after gene transfer, myocardial -gal expression was
measured by ELISA.
RESULTS Selective retroinfusion into the anterior cardiac vein substantially increased reporter gene
expression (1,039 79 pg -gal/mg protein) in the targeted left anterior descending coronary
artery territory when compared with surgical (448  127, p  0.05) and PIMD (842  145,
p  0.05). Both IMD approaches showed an inhomogenous -gal expression, particularly
along the injection sites, while retroinfusion resulted in a more homogenous transmural gene
expression.
CONCLUSIONS Percutaneous selective pressure-regulated retroinfusion compares favorably with surgical and
percutaneous intramyocardial injection techniques by providing a more homogenous and even
more efficient adenoviral gene delivery. (J Am Coll Cardiol 2004;44:1124–9) © 2004 by the
American College of Cardiology Foundatione
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Tvariety of emerging molecular interventions are being
esigned to treat coronary artery disease and heart failure.
ome of these strategies are cell-based (1–4), whereas
thers depend on proteins (5), naked complementary de-
xyribonucleic acid integration (6), or viral vector gene
ransfer (7,8). Efficient substrate delivery to the targeted
yocardial region is of crucial importance for each of these
trategies. The majority of recent clinical studies aimed at
nducing angiogenesis were based on intracoronary (8) or
irect myocardial injection techniques (7,9). Both delivery
trategies appeared to be safe in phase I and phase II clinical
rials (7–9) but failed to demonstrate significant improve-
ent of perfusion or clinical end points. The major draw-
ack of intracoronary injection is limited retention of
ngiogenic substrates (10,11), whereas direct myocardial
njection has to overcome limited spatial distribution (12).
lthough intramyocardial injection is considered to be the
referred delivery strategy so far, a more homogenous, but
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ermany; and the †Department of Cardiology, Heart Center, University of Leipzig,
eipzig, Germany. Dr. Boekstegers is a consultant of Genzyme, Inc.
Manuscript received January 15, 2004; revised manuscript received April 28, 2004,“ccepted May 3, 2004.qually efficient, delivery might be required before regional
yocardial blood supply or function can be substantially
nfluenced by angiogenic or arteriogenic agents.
Percutaneous selective pressure-regulated retroinfusion of
oronary veins (11,13,14) combines homogenous intravas-
ular delivery with increased retention of angiogenic sub-
trates. It has been shown previously to provide substantially
igher and more homogenous gene expression after adeno-
iral reporter gene transfer when compared with intracoro-
ary delivery (11). Moreover, favorable retention of angio-
enic FGF-2 protein with functionally relevant induction of
rterio- and angiogenesis was demonstrated recently in a pig
odel of chronic myocardial ischemia (15).
In this study, we addressed adenoviral gene transfer using
ercutaneous selective pressure-regulated retroinfusion and,
or the first time, compared it directly with surgical and
ercutaneous intramyocardial delivery (PIMD) in a pig
odel.
ETHODS
he present investigation was carried out according to the
Guide for the Care and Use of Laboratory Animals” and
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Fifteen German farm pigs (mean body weight, 26  4
g) were anesthetized and monitored as described previously
11,15). Catheter introducer sheaths were placed in the
ight carotid artery and right external jugular vein. Full
nticoagulation was achieved by bolus injection of heparin
0,000 IU followed by continuous application of 5,000
E/h. At the end of the experiment, all catheters and
ntroducer sheaths were removed. Seven days later the
nimal was anesthetized again and intubated, and catheter
ntroducer sheaths were placed as decribed above. The
atency of the left anterior descending (LAD) artery was
onfirmed by coronary angiography. Thereafter, the heart
as excised and the left ventricle (LV) was cut into slices of
-cm thickness from the apex to the basis as described
reviously (15). Each slice was divided into eight transmural
egments, and each segment was separated equally into an
picardial (EPI) probe, a midmyocardial (MID) probe, and
subendocardial (ENDO) probe (Fig. 1).
atheterization procedures. In all animals, a 7-F guiding
atheter was placed in the left coronary artery, and the
AD artery was wired. During the delivery of the adeno-
iral vectors, the LAD was occluded for 10 min by a
ercutaneous transluminal coronary angioplasty balloon
istal to the first diagonal branch in all groups. In pigs
reated by selective retroinfusion, the anterior interventric-
lar vein was catheterized using a 6-F retroinfusion catheter
11,13,16,17).
elective retroinfusion. The system of selective suction
nd pressure-regulated retroinfusion has been described in
etail previously (11,13,16,17). For regional application of
denoviral vectors, a modified technique of continuous
ressure-regulated retroinfusion was used with inactivation
f the suction device (11). Briefly, the high-pressure reser-
oir (2.5 atm) was filled with saline solution (0.9%) that was
ept at 37°C. The adenoviral vector solution (5  109
laque forming unit [pfu] diluted in 20 ml saline) was
elivered during 10 min of continuous retroinfusion.
urgical intramyocardial delivery. In animals randomized
or surgical intramyocardial delivery (IMD), a left thoracot-
my was performed. After incision of the pericardium, the
denoviral vectors were injected with a 27-gauge needle. For
ach injection, the needle was advanced about 10 mm
Abbreviations and Acronyms
ENDO  endomyocardial (probe or layer)
EPI  epicardial (probe or layer)
IMD  intramyocardial delivery
LAD  left anterior descending (coronary artery)
LV  left ventricle/ventricular
MID  midmyocardial (probe or layer)
PIMD  percutaneous intramyocardial delivery
-gal  beta-galactosidaseerpendicular to the surface of the heart into the myocar-ium. Sixteen injections of 100 l adenoviral vector con-
aining solution (5  109 pfu diluted in 1.6 ml saline) were
pplied distal to first diagonal branch into the LAD
erritory.
IMD. An endoventricular injection catheter (Steerjet,
icroHeart, Boston, Massachusetts) was placed across the
ortic valve in the LV cavity; 16 injections of 100 l
denoviral vector containing solution into the LV septum
nd anterior LV wall were performed under fluoroscopic
ontrol.
denoviral vectors and analysis of gene transfer. A
eplication-deficient, second generation adenoviral vector
arrying the beta-galactosidase (-gal)/lacZ reporter gene
Ad2-CMV--Gal, Genzyme, Boston, Massachusetts) was
sed. The -gal concentration in each myocardial probe was
uantified using an ELISA (18). For histologic assessment
f -gal, representative samples of the LAD region were
cquired and processed as described previously (11).
xperimental groups and statistics. Three experimental
roups (A to C) were randomly assigned. In group A (n 
), the adenoviral vectors were injected using a surgical
pproach (i.e., an IMD). Percutaneous intramyocardial
njection (i.e., a PIMD) was performed in group B (n  5).
n group C (n  5), adenoviral vectors were delivered by
etroinfusion.
igure 1. Harvesting of myocardial probes for measurement of regional
yocardial beta-galactosidase concentration. After excision of the heart,
he left ventricle (LV) was sliced parallel to the short axis from the apex to
he basis. Each slice was divided into segments of equal size followed by
ividing each segment into a epicardial (EPI), midmyocardial (MID), and
ubendocardial (ENDO) probe. RV  right ventricle.All values are presented as mean  SEM. Measurements
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Myocardial Gene Delivery by Retroinfusion September 1, 2004:1124–9f -gal expression were analyzed by nonparametric
ruskal-Wallis test. Whenever a statistically significant
ffect was obtained, we performed multiple comparison tests
etween the individual groups using the Mann-Whitney U
est. A p value 0.05 was considered to be statistically
ignificant.
ESULTS
he three groups were similar with regard to body weight
nd hemodynamics at baseline and day 7. Coronary angio-
rams performed at day 0 and day 7 showed no evidence for
ompromised coronary flow.
fficiency of surgical IMD. At day 7 after surgical IMD
f adenoviral vectors (group A), quantitative ELISA of
-gal expression revealed significant reporter gene expres-
ion in 20.2  3.3% of all myocardial probes (n  330) in
he targeted LAD territory. The mean -gal expression in
he LAD territory was 448  127 pg/mg protein (Fig. 2).
here was a significantly higher -gal expression in the EPI
robes than in the MID probes and neglegible expression in
he subendocardial probes (Figs. 3 and 4).
fficiency of catheter-based PIMD. In group B with
IMD, significant -gal expression was observed in 14.4 
.6% of all myocardial probes (n  321) in the targeted
AD territory. In contrast with group A, the highest levels
f -gal expression were found in the MID and subendo-
ardial probes, whereas epicardial expression was very low
Figs. 3 and 4).
fficiency of selective retrograde delivery into coronary
eins. Retrograde delivery of adenoviral vectors resulted in
ignificantly increased reporter gene expression in the target
AD territory (1,039  79 pg -gal/mg protein) compared
ith surgical (448  127 pg/mg, p  0.05) and percutane-
us IMD (842  145 pg/mg, p  0.05) (Fig. 2). In
ddition, -gal expression was present in significantly more
robes of group C (46.2  3.8% of n  317 myocardial
robes) than in group A (20.2  3.3%, n  330, p  0.05)
igure 2. Mean transmyocardial beta-galactosidase expression in the left
nterior descending coronary artery territory (open bars) and in the
ontrol, circumflex coronary artery area (solid bars) seven days after
pplication of 5 109 pfu Ad2-CMV-beta-galactosidase. IMD surgical
ntramyocardial delivery (group A); PIMD  percutaneous intramyocar-
ial delivery (group B); retroinfusion  pressure-regulated retroinfusion of
he anterior cardiac vein (group C). Mean SEM, n 5/group. *p 0.05
roup C vs. group A and group B.nd group B (14.4 0.6%, n 321, p 0,05). As expected (rom previous studies (11), there was a gradient from EPI to
ID and ENDO layers (Figs. 3 and 4).
istochemical analysis of -gal expression. Histologic
xamination of the hearts transfected with the Ad2-CMV-
-gal showed positive staining of cardiac myocytes (Fig. 5).
fter direct surgical intramyocardial injection, positive car-
iomyocytes were detected, particularly along the injection
ites in the subepicardial myocardium. Percutaneous direct
ntramyocardial injection revealed a similar gene expression
attern longitudinal along the injection channel, mainly in
he midmyocardium and in subendocardial layers (Fig. 5A).
n contrast, after retroinfusion, a more homogeneous dis-
ribution of positive staining cells was observed in all
yocardial layers (Fig. 5B). There was no evidence for
icro-infarctions in these probes determined by histologic
ssessment, arguing against false positive -gal staining
19).
ransfection of non-targeted myocardium. Selective
ene transfer to the target LAD territory after intramyocar-
ial (IMD, group A and PIMD, group B) and retrograde
elivery (retroinfusion, group C) was confirmed by very low
mounts of -gal expression in all probes of the control
egion (circumflex coronary artery territory) (Fig. 2).
ISCUSSION
iming at a catheter-based approach for efficient and
omogeneous myocardial gene delivery, we developed a
ressure-regulated system for selective retroinfusion of cor-
nary veins (11), which allows a unique access to ischemic
yocardium regardless of occluded or diffusely stenotic
oronary arteries (11). In previous studies, we could dem-
nstrate that selective pressure-regulated retroinfusion of
oronary veins was more efficient than intracoronary arterial
elivery with regard to adenoviral gene transfer (11) and to
yocardial retention of angiogenic FGF-2 protein (15). In
his study, adenoviral gene transfer by selective retroinfusion
as compared directly with surgical and percutaneous in-
ramyocardial injection, which have been recommended as
he preferred gene delivery strategies so far (20). Interest-
ngly, selective retroinfusion compared favorably with in-
ramyocardial injection, not only by inducing a more ho-
ogeneous myocardial distribution but also by increasing
he efficacy of adenoviral-mediated gene transfer. At the
ame time, selectivity of gene transfer by retroinfusion was
imilar to the intramyocardial injection techniques (Fig. 2).
After retrograde delivery into the coronary vein, the
denoviral vectors are exposed to the coronary venous
ystem with a large endothelial surface. Apparently, wide-
pread transmural transfection occurred after retrograde
elivery, by contrast with distinct local transfection after
ntramyocardial injection (Fig. 3). This is in agreement with
revious studies using selective pressure-regulated retroin-
usion of adenoviral vectors (11) as well as of plasmids
ncoding for constitutive endothelial nitric oxide synthase
21). Recently, high-pressure retrograde delivery of plas-
m
p
g
o
h
p
r
a
b
o
d
b
F
r
(
s
1127JACC Vol. 44, No. 5, 2004 Raake et al.
September 1, 2004:1124–9 Myocardial Gene Delivery by Retroinfusionids encoding for human Del-1 has also been shown to
rovide widespread myocardial transfection (22).
In pigs treated by retrograde gene delivery, a gradient in
ene expression from the EPI to the ENDO layers was
bserved in line with previous findings, probably due to the
igher vascular resistance in the endomyocardium (11,23).
The difference in transfection between EPI and ENDO
igure 3. Representative maps of the regional myocardial beta-galact
etroinfusion of the anterior cardiac vein (retroinfusion), surgical intram
PIMD). Each map represents one animal. ENDO  subendocardial prob
olid bars  MID; hatched bars  ENDO.robes, however, was less pronounced for pigs treated by detroinfusion than for pigs treated by surgical IMD (Figs. 3
nd 4) arguing again for a more homogeneous gene delivery
y retroinfusion.
To the best of our knowledge, the transmural distribution
f gene expression has not been studied after intramyocar-
ial injection, particularly with regard to the difference
etween surgical epicardial injection and percutaneous en-
se protein expression after catheter-based selective pressure-regulated
dial direct injection (IMD), and percutaneous intramyocardial injection
I  epicardial probe; MID  midmyocardial probe. Open bars  EPI;osida
yocar
e; EPocardial injection. The finding of very low endocardial
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Myocardial Gene Delivery by Retroinfusion September 1, 2004:1124–9evels after surgical epicardial injection (via IMD) is in
greement with other studies pointing out that there was
mmediate loss of material due to direct leakage (12). In
ddition, the injected material may exit the myocardium via
ardiac veins or lymphatic channels (12). In light of the fact
hat part of the venous drainage is blocked during retrograde
elivery, this might be another reason for increased reten-
ion (21) and adenoviral transfection by retroinfusion.
In contrast with surgical epicardial injection, percutane-
us endocardial delivery was associated with very low
picardial levels of gene expression (Figs. 3 and 4). Al-
hough after endocardial delivery the overall gene expression
as significantly higher than after epicardial delivery (Fig.
igure 4. Mean beta-galactosidase expression after adenoviral transfection
n the epicardial (EPI), midmyocardial (MID), and subendocardial
ENDO) layers of the targeted left anterior descending coronary territory.
ean  SEM, n  5/group. **p  0.05 group C vs. group A and group
; *p  0.05 group C vs. group A; #p  0.05 group A vs. group B; p 
.05 group B vs. group A. Line with diamonds  retroinfusion; line with
riangles  percutaneous intramyocardial delivery; line with squares 
urgical intramyocardial delivery.
igure 5. Histochemical detection of beta-galactosidase seven days after ad
ressure-regulated retroinfusion of the adenoviral vectors into the coronary vein), this was associated with a spotty inhomogeneous distri-
ution. More sophisticated percutaneous endocardial injec-
ion systems (24) and a higher number of injections might
mprove transfection rates and homogeneity. However,
istologic assessment of -gal expression showing high
evels of expression only at the site of injection (Fig. 5)
rgues against this strategy. If microparticle retention and
denoviral transfection were compared after percutaneous
ndomyocardial injection using different volumes of injec-
ion, very small injection volumes (10 l) were associated
ith almost complete (98%) microparticle retention, by
ontrast with higher volumes (100 l) with about 20%
etention (12). However, there was only a non-significant
rend toward improved transfection associated with the
maller injection volumes (12). Therefore, it is unlikely that
he results of this study would have been changed substan-
ially by using smaller injection volumes. More likely,
maller injection volumes would have increased further the
nhomogeneity of gene expression after intramyocardial
njection.
Selective regional myocardial infiltration by the percuta-
eous coronary venous route (25) is an alternative approach
o direct intramyocardial injection and is taking advantage
f the nondiseased coronary veins as an access to ischemic
yocardium similar to selective retroinfusion. Whether
denoviral transfection, drug, or cell delivery (3) is the
rimary objective, epicardial injection using the coronary
enous system faces the same limitations as pointed out for
he techniques of intramyocardial injections used in this
tudy.
In summary, percutaneous selective pressure-regulated
etroinfusion compares favorably with surgical and percuta-
eous intramyocardial injection techniques by providing a
ral transfection by percutaneous intramyocardial delivery (A) and selectiveenovi
(B) (original magnification  80).
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September 1, 2004:1124–9 Myocardial Gene Delivery by Retroinfusionore homogenous and even more efficient adenoviral gene
elivery.
With regard to the well-known safety of selective retro-
nfusion in patients with coronary artery disease (13,26), this
s a promising percutaneous delivery technique for genes
hat might require a more homogenous transmural myocar-
ial distribution. To the best of our knowledge, no data are
vailable so far concerning whether biological activity is
reater when a small area has high levels of gene expression
r whether a larger area has lower or equal levels of gene
xpression. Therefore, ongoing preclinical studies will de-
ermine whether more homogenous and efficient myocardial
ene transfer by selective pressure-regulated retroinfusion
ranslates into higher biological activity of gene and cell
elivery.
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